Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC3402 + durvalumab in advanced hepatocellular carcinoma
NCT06111326Phase 2Not yet recruiting
- Sponsor
- BioCity Biopharma
- Start
- Oct 2023
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BC3402 in hepatocellular carcinoma (HCC), sponsored by BioCity Biopharma. Primary endpoints: Incidence of Dose Limiting Toxicity at 28 days, Safety at 2 years and 1 more. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
BC3402
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06111326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111326.